<DOC>
	<DOCNO>NCT00601978</DOCNO>
	<brief_summary>This study evaluate effect immediate release ( IR ) carbidopa levodopa versus effect immediate-release carbidopa/levodopa ERP parameter patient idiopathic PD .</brief_summary>
	<brief_title>Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone Markers Event Related Potentials ( ERPs ) Patients With Idiopathic Parkinson 's Disease ( PD ) End-of-dose Wearing Off</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Male female patient age 45 75 year ( inclusive ) 2 . Patients MMSE score least 25 screen visit . 3 . Patients experience EODWO , reemergence PD symptom wake hour , determine WOQ9 score least one motor symptom wear 4 . Patients take stable dose immediaterelease carbidopa/levodopa least 4 week prior randomization , equivalent total daily dose levodopa 300 600 mg/day . 5 . Patients , investigator 's judgement , capable satisfying requirement protocol 6 . Patients willing able give write informed consent accord legal requirement . 1 . Diagnosis secondary parkinsonism , atypical Parkinson 's disease , history , sign , symptom suggest diagnosis . 2 . Unstable Parkinson 's disease determine investigator . 3 . Disabling dyskinesia ( score &gt; 2 Unified Parkinson 's Disease Rating Scale [ UPDRS ] question # 32 , score &gt; 2 UPDRS question # 33 ) . 4 . Treatment carbidopa/levodopa controlledrelease extendedrelease formulation ( bedtime administration acceptable ) . The use controlledrelease carbidopa/levodopa allow even visit efficacy assessment occur . 5 . Concomitant previous treatment certain medication supplement specify protocol . 6 . Patients unable comply dose requirement protocol , first dose study medication take time first EEG second dose take completion third EEG . 7 . Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSMIVTR ; diagnosis 1. dementia ( cause ) ; 2. moderate severe major depression , present independent time first diagnosis PD , define QIDSSR16 score &gt; 15 ; 3. generalize anxiety disorder panic disorder make prior diagnosis PD . 8 . DSMIVTR diagnosis alcohol substance abuse ( exclude nicotine caffeine ) 3 month prior randomization ) alcohol substance dependence ( exclude nicotine caffeine ) 6 month prior randomization . Alcohol avoid within 12 hour precede Week 6 Week 12 visit . 9 . Nicotine use &gt; 5 cigarette ( equivalent form administration ) per day . Nicotine use permit day Week 6 Week 12 visit . 10 . Ingestion &gt; 4 caffeinated beverage ( equivalent form administration ) per day . 11 . History major head injury , include skull fracture penetrate head injury , history brain surgery . 12 . Past current treatment deep brain stimulation . 13 . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . 14 . Hearing loss impairment may prevent reliability test result use auditory evoked potential .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>carbidopa/levodopa/entacapone</keyword>
	<keyword>carbidopa/levodopa</keyword>
	<keyword>non-motor symptom</keyword>
	<keyword>event-related potential</keyword>
	<keyword>ERP</keyword>
	<keyword>EEG</keyword>
	<keyword>electroencephalogram</keyword>
</DOC>